Journal Title：Cancer Biology & Therapy

Cancer, the second leading cause of death, is a heterogenous group of over 100 diseases. Cancer is characterized by disordered and deregulated cellular and stromal proliferation accompanied by reduced cell death with the ability to survive under stresses of nutrient and growth factor deprivation, hypoxia, and loss of cell-to-cell contacts. At the molecular level, cancer is a genetic disease that develops due to the accumulation of mutations over time in somatic cells. The phenotype includes genomic instability and chromosomal aneuploidy that allows for acceleration of genetic change. Malignant transformation and tumor progression of any cell requires immortalization, loss of checkpoint control, deregulation of growth, and survival. A tremendous amount has been learned about the numerous cellular and molecular genetic changes and the host-tumor interactions that accompany tumor development and progression. It is the goal of the field of Molecular Oncology to use this knowledge to understand cancer pathogenesis and drug action, as well as to develop more effective diagnostic and therapeutic strategies for cancer. This includes preventative strategies as well as approaches to treat metastases. With the availability of the human genome sequence and genomic and proteomic approaches, a wealth of tools and resources are generating even more information. The challenge will be to make biological sense out of the information, to develop appropriate models and hypotheses and to translate information for the clinicians and the benefit of their patients. Cancer Biology & Therapy aims to publish original research on the molecular basis of cancer, including articles with translational relevance to diagnosis or therapy. We will include timely reviews covering the broad scope of the journal. The journal will also publish op-ed pieces and meeting reports of interest. The goal is to foster communication and rapid exchange of information through timely publication of important results using traditional as well as electronic formats. The journal and the outstanding Editorial Board will strive to maintain the highest standards for excellence in all activities to generate a valuable resource.

癌癥是第二大死亡原因，是一類(lèi)由 100 多種疾病組成的異質(zhì)性疾病。癌癥的特征是細(xì)胞和基質(zhì)增殖紊亂和失調(diào)，伴隨細(xì)胞死亡減少，在營(yíng)養(yǎng)和生長(zhǎng)因子缺乏、缺氧和細(xì)胞間接觸喪失的壓力下仍能存活。在分子水平上，癌癥是一種遺傳性疾病，是由于體細(xì)胞中突變隨時(shí)間積累而發(fā)展起來(lái)的。其表型包括基因組不穩(wěn)定性和染色體非整倍性，這加速了基因變化。任何細(xì)胞的惡性轉(zhuǎn)化和腫瘤進(jìn)展都需要永生化、檢查點(diǎn)控制喪失、生長(zhǎng)失調(diào)和存活。人們對(duì)伴隨腫瘤發(fā)展和進(jìn)展的眾多細(xì)胞和分子遺傳變化以及宿主-腫瘤相互作用有了大量的了解。分子腫瘤學(xué)領(lǐng)域的目標(biāo)是利用這些知識(shí)來(lái)了解癌癥的發(fā)病機(jī)制和藥物作用，以及開(kāi)發(fā)更有效的癌癥診斷和治療策略。這包括預(yù)防策略以及治療轉(zhuǎn)移的方法。隨著人類(lèi)基因組序列以及基因組和蛋白質(zhì)組學(xué)方法的出現(xiàn)，大量的工具和資源正在產(chǎn)生更多的信息。挑戰(zhàn)在于從信息中得出生物學(xué)意義，開(kāi)發(fā)適當(dāng)?shù)哪Ｐ秃图僭O(shè)，并為臨床醫(yī)生和患者提供信息?！栋┌Y生物學(xué)與治療》旨在發(fā)表關(guān)于癌癥分子基礎(chǔ)的原創(chuàng)研究，包括與診斷或治療具有轉(zhuǎn)化相關(guān)性的文章。我們將及時(shí)發(fā)表涵蓋期刊廣泛范圍的評(píng)論。該期刊還將發(fā)表感興趣的評(píng)論文章和會(huì)議報(bào)告。目標(biāo)是通過(guò)使用傳統(tǒng)和電子格式及時(shí)發(fā)表重要結(jié)果來(lái)促進(jìn)溝通和快速信息交換。該期刊和優(yōu)秀的編輯委員會(huì)將努力在所有活動(dòng)中保持最高的卓越標(biāo)準(zhǔn)，以產(chǎn)生寶貴的資源。

Cancer Biology & Therapy創(chuàng)刊于2002年，由Landes Bioscience出版商出版，收稿方向涵蓋醫(yī)學(xué) - 腫瘤學(xué)全領(lǐng)域，此期刊水平偏中等偏靠后，在所屬細(xì)分領(lǐng)域中專業(yè)影響力一般，過(guò)審相對(duì)較易，如果您文章質(zhì)量佳，選擇此期刊，發(fā)表機(jī)率較高。平均審稿速度 約2.3月 ，影響因子指數(shù)4.4，該期刊近期沒(méi)有被列入國(guó)際期刊預(yù)警名單，廣大學(xué)者值得一試。